BR100 Increased By (0.08%)
BR30 Increased By (0.53%)
KSE100 Increased By (0.28%)
KSE30 Increased By (0.29%)
AGHA 6.35 Increased By ▲ 0.03 (0.47%)
BECO 4.39 Increased By ▲ 0.12 (2.81%)
BML 62.50 Increased By ▲ 0.05 (0.08%)
BOP 31.47 Increased By ▲ 0.24 (0.77%)
CNERGY 11.70 Increased By ▲ 0.11 (0.95%)
CSIL 5.92 Increased By ▲ 0.20 (3.5%)
FCCL 61.60 Increased By ▲ 0.06 (0.1%)
FFL 14.79 Decreased By ▼ -0.23 (-1.53%)
FNEL 1.23 No Change ▼ 0.00 (0%)
KEL 6.33 Increased By ▲ 0.07 (1.12%)
KOSM 5.90 Increased By ▲ 0.34 (6.12%)
LOTCHEM 24.79 Increased By ▲ 0.11 (0.45%)
MLCF 103.93 Decreased By ▼ -0.15 (-0.14%)
NBP 173.05 Decreased By ▼ -2.23 (-1.27%)
NCPL 51.85 Decreased By ▼ -0.92 (-1.74%)
NPL 54.19 Increased By ▲ 0.07 (0.13%)
OGDC 315.50 Increased By ▲ 2.11 (0.67%)
PACE 9.26 Increased By ▲ 0.06 (0.65%)
PAEL 35.51 Decreased By ▼ -0.29 (-0.81%)
PIBTL 13.65 Increased By ▲ 0.18 (1.34%)
PPL 226.60 Increased By ▲ 4.79 (2.16%)
PRL 80.30 Increased By ▲ 1.22 (1.54%)
PTC 46.89 Increased By ▲ 0.04 (0.09%)
SSGC 23.90 Increased By ▲ 0.03 (0.13%)
TBL 9.30 Decreased By ▼ -0.01 (-0.11%)
TELE 7.65 Increased By ▲ 0.26 (3.52%)
TPL 24.51 Decreased By ▼ -0.60 (-2.39%)
TPLP 13.04 Increased By ▲ 0.53 (4.24%)
TREET 26.05 Decreased By ▼ -0.20 (-0.76%)
TRG 53.38 Decreased By ▼ -0.06 (-0.11%)
World

Singapore approves anti-viral drug for COVID-19 patients

  • The US authorised the emergency use of remdesivir in hospitals at the start of May, followed by Japan and South Korea, while Europe has been considering following suit.
Published Updated
By

SINGAPORE: Singapore has approved the use of the anti-viral drug remdesivir to treat seriously ill coronavirus patients, authorities said Wednesday, becoming the latest country to do so.

The US authorised the emergency use of remdesivir in hospitals at the start of May, followed by Japan and South Korea, while Europe has been considering following suit.

It has been granted conditional approval in Singapore for treatment of some adult virus patients, such as those who require intensive breathing support, the country's health products regulator said.

The regulator, the Health Sciences Authority, said it had "expedited the review of remdesivir given the urgent public health need during the COVID-19 pandemic".

As a condition for the approval, the authority requires US-based Gilead Sciences, which developed the drug, to collect safety data and monitor its use.

Singapore initially kept the virus in check with a strict regime of testing and contact tracing, only for serious outbreaks to emerge later in dormitories housing low-paid foreign workers.

The city-state now has the highest recorded number of infections in Southeast Asia with nearly 39,000 cases, mostly among foreign workers. The death toll stands at 25.

Comments

Comments are closed for this article.